We have utilized a version 2.0 of our Fusion gene microarray (version 1.0 described by PMID: 19152679 and GEO, GPL8078) to screen cancer cell lines for known fusion genes We assembled a comprehensive
Results of LentiMutate on EGFRdel746-750 cDNA packaged using M-RT and osimertinib in the HCC827 cell line. Values shown are the averages of two biological replicates. The fold enrichment of "All nucle
Additional file 2: Table S2. Cancer surveillance and prophylactic surgery recommendations referred to for determining actionability of findings identified in eGT.
Introduction: Ashkenazi Jewish (AJ) individuals face a 1 in 40 (2.5%) risk of having a BRCA mutation, which is 10 times the general population risk. JScreen launched the PEACH BRCA Study, a telehealth
